The value of blood cytokines and chemokines in assessing COPD
Public DepositedAdd to collection
You do not have access to any existing collections. You may create a new collection.
Downloadable Content
Download PDFCitation
MLA
Bradford, Eric, et al. The Value of Blood Cytokines and Chemokines In Assessing Copd. BioMed Central, 2017. https://doi.org/10.17615/qnkw-w644APA
Bradford, E., Jacobson, S., Varasteh, J., Comellas, A., Woodruff, P., O’neal, W., De Meo, D., Li, X., Kim, V., Cho, M., Castaldi, P., Hersh, C., Silverman, E., Crapo, J., Kechris, K., & Bowler, R. (2017). The value of blood cytokines and chemokines in assessing COPD. BioMed Central. https://doi.org/10.17615/qnkw-w644Chicago
Bradford, Eric, Sean Jacobson, Jason Varasteh, Alejandro P Comellas, Prescott Woodruff, Wanda K O’neal, Dawn L De Meo et al. 2017. The Value of Blood Cytokines and Chemokines In Assessing Copd. BioMed Central. https://doi.org/10.17615/qnkw-w644- Creator
-
Bradford, Eric
- Other Affiliation: Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, USA
-
Jacobson, Sean
- Other Affiliation: Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, USA
-
Varasteh, Jason
- Other Affiliation: Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, USA
-
Comellas, Alejandro P
- Other Affiliation: University of Iowa, Internal Medicine, Iowa City, USA
-
Woodruff, Prescott
- Other Affiliation: UCSF, Division of Pulmonary and Critical Care Medicine and Cardiovascular Research Institute, San Francisco, USA
-
O’Neal, Wanda K
- Affiliation: School of Medicine, Cystic Fibrosis and Pulmonary Diseases Research and Treatment Center
-
DeMeo, Dawn L
- Other Affiliation: Division of General Internal Medicine and Primary Care, Brigham and Women’s Hospital, Boston, USA
-
Li, Xingnan
- Other Affiliation: Department of Medicine, University of Arizona College of Medicine, Tucson, USA
-
Kim, Victor
- Other Affiliation: Temple University School of Medicine, Pulmonary and Critical Care Medicine, Philadelphia, USA
-
Cho, Michael
- Other Affiliation: Channing Division of Network Medicine and the Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
-
Castaldi, Peter J
- Other Affiliation: Division of General Internal Medicine and Primary Care, Brigham and Women’s Hospital, Boston, USA; Tufts Medical Center, ICRHPS, Boston, USA
-
Hersh, Craig
- Other Affiliation: Division of General Internal Medicine and Primary Care, Brigham and Women’s Hospital, Boston, USA
-
Silverman, Edwin K
- Other Affiliation: Channing Division of Network Medicine and the Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
-
Crapo, James D
- Other Affiliation: Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, USA
-
Kechris, Katerina
- Other Affiliation: Department of Biostatistics and Informatics, University of Colorado Denver, Colorado School of Public Health, Aurora, USA
-
Bowler, Russell P
- Other Affiliation: Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, USA; Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Denver, University of Colorado Anschutz Medical Campus, Aurora, USA
- Abstract
- Abstract Background Blood biomarkers are increasingly used to stratify high risk chronic obstructive pulmonary disease (COPD) patients; however, there are fewer studies that have investigated multiple biomarkers and replicated in multiple large well-characterized cohorts of susceptible current and former smokers. Methods We used two MSD multiplex panels to measure 9 cytokines and chemokines in 2123 subjects from COPDGene and 1117 subjects from SPIROMICS. These biomarkers included: interleukin (IL)-2, IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, eotaxin/CCL-11, eotaxin-3/CCL-26, and thymus and activation-regulated chemokine (TARC)/CCL-17. Regression models adjusted for clinical covariates were used to determine which biomarkers were associated with the following COPD phenotypes: airflow obstruction (forced expiratory flow at 1 s (FEV1%) and FEV1/forced vital capacity (FEV1/FVC), chronic bronchitis, COPD exacerbations, and emphysema. Biomarker-genotype associations were assessed by genome-wide association of single nucleotide polymorphisms (SNPs). Results Eotaxin and IL-6 were strongly associated with airflow obstruction and accounted for 3–5% of the measurement variance on top of clinical variables. IL-6 was associated with progressive airflow obstruction over 5 years and both IL-6 and IL-8 were associated with progressive emphysema over 5 years. None of the biomarkers were consistently associated with chronic bronchitis or COPD exacerbations. We identified one novel SNP (rs9302690 SNP) that was associated with CCL17 plasma measurements. Conclusion When assessing smoking related pulmonary disease, biomarkers of inflammation such as IL-2, IL-6, IL-8, and eotaxin may add additional modest predictive value on top of clinical variables alone. Trial registration COPDGene (ClinicalTrials.gov Identifier: NCT02445183 ). Subpopulations and Intermediate Outcomes Measures in COPD Study (SPIROMICS) ( ClinicalTrials.gov Identifier: NCT 01969344 ).
- Date of publication
- October 24, 2017
- DOI
- Identifier
- Resource type
- Article
- Rights statement
- In Copyright
- Rights holder
- The Author(s).
- Language
- English
- Bibliographic citation
- Respiratory Research. 2017 Oct 24;18(1):180
- Publisher
- BioMed Central
Relations
- Parents:
This work has no parents.
Items
Thumbnail | Title | Date Uploaded | Visibility | Actions |
---|---|---|---|---|
12931_2017_article_662.pdf | 2019-05-07 | Public | Download | |
12931_2017_662_moesm1_esm.docx | 2019-05-07 | Public | Download | |
12931_2017_662_moesm2_esm.pdf | 2019-05-07 | Public | Download | |
12931_2017_662_moesm3_esm.pdf | 2019-05-07 | Public | Download |